Gilead Sciences, Inc. (NASDAQ: GILD), one of the world’s leading biopharmaceutical companies, is headquartered in Foster City, California. Today, Gilead CEO Daniel O’Day serves as Chairman and Chief Executive Officer, leading a company with $29.4 billion in annual revenue and a workforce of approximately 18,000 employees. Appointed in March 2019 after a distinguished 30-year career at Roche, O’Day has transformed Gilead from an HIV-focused company into a diversified biopharma powerhouse. Under his leadership, Gilead navigated the COVID-19 pandemic with remdesivir (Veklury), completed the landmark $21 billion Immunomedics acquisition, and secured FDA approval for lenacapavir (Yeztugo) — the first twice-yearly injectable for HIV prevention.

(Suggested: Pfizer CEO Email & Net Worth – Albert Bourla Salary)

Daniel O’Day – Quick Facts

Gilead Sciences Competitors

Gilead Sciences operates in the highly competitive biopharmaceutical industry, primarily focusing on HIV/AIDS, oncology, liver diseases, and inflammatory conditions. The key competitors of Gilead Sciences include:

• Johnson & Johnson – Janssen Pharmaceuticals HIV and oncology portfolios
• AbbVie – Hepatitis C (Mavyret) and oncology
• Bristol-Myers Squibb – Oncology and immunology therapeutics
• Merck & Co. – HIV (Isentress) and immuno-oncology (Keytruda)
• ViiV Healthcare (GSK/Pfizer/Shionogi) – Long-acting HIV treatments (Cabenuva)
• Roche – Oncology and diagnostics
• Amgen – Oncology and inflammation biologics
• Moderna – mRNA-based infectious disease therapeutics

Daniel O’Day Net Worth 2026 – Gilead CEO Salary

As of 2026, Daniel O’Day’s net worth is estimated at approximately $81 million or more, based on his disclosed Gilead Sciences stock holdings and SEC filings. O’Day directly owns approximately 556,698 shares of Gilead Sciences (GILD), accumulated through years of stock awards and purchases. Over the past year, he has sold a total of 205,640 shares while retaining substantial equity in the company.

Gilead CEO Compensation Breakdown (FY2024)

Gilead Sciences Net Worth 2026 – Is Gilead Profitable?

Yes, Gilead Sciences is a highly profitable biopharmaceutical company. Under CEO Daniel O’Day, Gilead has delivered consistent revenue growth driven by its dominant HIV franchise and expanding oncology portfolio. The company reported full-year 2025 revenues of $29.4 billion and diluted EPS of $6.78, a dramatic recovery from FY2024’s $0.38 EPS (which was depressed by one-time IPR&D impairment charges).

Gilead Sciences Financial Summary

(Recommended: Johnson & Johnson CEO Email & Net Worth – Joaquin Duato Salary)

Gilead CEO Email Address | Daniel O’Day Contact

Below are the official contact details for Gilead Sciences CEO Daniel O’Day:

Career & Education – Company, University, & College

Daniel O’Day’s career spans over three decades in the global pharmaceutical industry, rising from entry-level positions at Roche to leading one of the world’s most important biopharmaceutical companies. Below is his complete career timeline:

Daniel O’Day Career Timeline

Daniel O’Day joined Roche straight out of business school in 1987, beginning what would become a remarkable 30-year tenure at the Swiss pharmaceutical giant. He held a succession of commercial and leadership roles, eventually rising to become CEO of Roche Diagnostics. He then served as CEO of Roche Pharmaceuticals, the company’s largest division, where he oversaw the development and commercialization of oncology blockbusters including Tecentriq and Hemlibra.

In December 2018, Gilead Sciences announced that O’Day would join as Chairman and CEO, effective March 2019. The appointment came at a pivotal moment for Gilead — the company had transformed HIV treatment with drugs like Sovaldi and Harvoni but was facing revenue headwinds as its hepatitis C franchise matured. O’Day was tasked with diversifying the pipeline and restoring growth.

(Related: AbbVie CEO Email & Net Worth – Robert Michael Salary)

Education

Daniel O’Day as Gilead CEO – Leadership & Achievements

Since taking the helm in March 2019, Daniel O’Day has executed a comprehensive transformation of Gilead Sciences. His tenure has been defined by bold strategic moves, rapid pandemic response, and pipeline diversification:

COVID-19 Response & Remdesivir

When the COVID-19 pandemic emerged in early 2020, O’Day led Gilead’s effort to develop and distribute remdesivir (Veklury), which became the first FDA-approved treatment for COVID-19 in October 2020. Under his direction, Gilead ramped production from 5,000 treatment courses to over 10 million per year, signing 127 generic licensing agreements to ensure global access. Veklury generated over $5.5 billion in sales at its peak in 2021.

The Immunomedics Acquisition

In September 2020, O’Day orchestrated Gilead’s largest acquisition ever — the $21 billion purchase of Immunomedics — to acquire Trodelvy (sacituzumab govitecan), a groundbreaking antibody-drug conjugate for the treatment of metastatic triple-negative breast cancer. This deal marked Gilead’s aggressive entry into oncology and has since expanded to multiple cancer indications, with Trodelvy generating $1.9 billion in sales by 2024.

Lenacapavir (Yeztugo) — A Game-Changing HIV Prevention

Perhaps O’Day’s most impactful achievement has been the development and approval of lenacapavir (Yeztugo), the world’s first twice-yearly injectable HIV prevention medication. The FDA approved Yeztugo for PrEP in June 2025, representing a paradigm shift from daily pills to semi-annual injections. In clinical trials, lenacapavir demonstrated 100% efficacy in preventing HIV in women. Gilead has partnered with the Global Fund to deliver lenacapavir to sub-Saharan Africa, beginning shipments to Eswatini and Zambia in late 2025.

Pipeline & Strategic Partnerships

Under O’Day, Gilead has built what he calls “the most robust pipeline in company history,” with over 50 clinical-stage programs. Key moves include a $4 billion partnership with Arcus Biosciences for oncology assets, the $4.3 billion acquisition of CymaBay Therapeutics in 2024 for liver disease treatment seladelpar, and a landmark $7.8 billion acquisition of Arcellx in 2025 to enter the CAR-T cell therapy space.

Daniel O’Day Wiki – Age, Family, & More

Gilead CEO Daniel O’Day (age 61, born May 26, 1964) was born in Texas but moved frequently as a child due to his father’s lengthy career at IBM. He is a third-generation Irish American with family roots in Ennis, County Clare, Ireland. O’Day has spoken publicly about his Irish heritage, stating: “The perseverance of my Irish ancestors is a daily motivation to me professionally and personally.”

O’Day is married to Mara Grace Dolan, and the couple have three children: Tierney, Meghan, and Brendan. The family is based in the San Francisco Bay Area, near Gilead’s Foster City headquarters. Family was central to O’Day’s upbringing — he is one of five siblings whose father instilled in them a deep appreciation for their heritage and the value of hard work.

Before entering the business world, O’Day worked as an Emergency Medical Technician (EMT) while in high school in Connecticut. He has credited this experience with sparking his lifelong passion for healthcare and medicine. He also held a job in landscaping — experiences that taught him the value of hard work before attending Georgetown University.

Notable Achievements & Board Memberships

• PhRMA Board Chair (2024) – Named chair of the Pharmaceutical Research and Manufacturers of America
• Georgetown University Board – Serves on the Board of Directors of his alma mater
• Columbia Business School Board – Active board member
• COVID-19 Response Leader – Led development and global distribution of remdesivir during the pandemic
• Irish America Business 100 – Honored by Irish America magazine for his contributions to business
• CNBC Featured Guest (Jan 2026) – Discussed Gilead’s pipeline and strategy at the JP Morgan Healthcare Conference

(Suggested: Merck CEO Email & Net Worth – Robert Davis Salary)

About Gilead Sciences

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California. Founded in 1987 by Michael L. Riordan, Gilead has grown into one of the world’s largest and most innovative biopharma companies, best known for its transformative antiviral therapies.

Gilead trades on the NASDAQ under the ticker symbol GILD. With full-year 2025 revenues of $29.4 billion and approximately 18,000 employees worldwide, Gilead remains one of the most valuable biopharmaceutical companies globally. The company operates research and manufacturing facilities in the United States, Ireland, Canada, and other countries.

Frequently Asked Questions (FAQ)

Who is the current CEO of Gilead Sciences?

The current CEO of Gilead Sciences is Daniel O’Day, who has served as Chairman and Chief Executive Officer since March 2019. Before joining Gilead, he spent 30 years at Roche, where he served as CEO of Roche Pharmaceuticals.

What is Daniel O’Day’s net worth in 2026?

As of 2026, Daniel O’Day’s net worth is estimated at $81 million or more, based on his disclosed Gilead Sciences stock holdings of approximately 556,698 shares. His substantial net worth reflects years of equity compensation and strategic stock retention.

What is Gilead CEO’s salary?

Daniel O’Day’s total compensation for fiscal year 2024 was $23.7 million, including a $1.8 million base salary, $16.5 million in equity awards, a $4 million annual bonus, and $1.4 million in other compensation. This represented a 5% increase over his 2023 package.

What is Gilead CEO’s email address?

Gilead Sciences CEO Daniel O’Day’s email address is [email protected]. He can also be reached via the company’s corporate headquarters at 333 Lakeside Drive, Foster City, CA 94404, or by phone at (650) 574-3000.

What did Daniel O’Day do before Gilead?

Before becoming Gilead CEO, Daniel O’Day spent 30 years at Roche, the Swiss pharmaceutical giant. He held progressively senior leadership roles, culminating in CEO of Roche Diagnostics and then CEO of Roche Pharmaceuticals, the company’s largest division.

Is Gilead Sciences a profitable company?

Yes, Gilead Sciences is highly profitable. In fiscal year 2025, the company reported total revenues of $29.4 billion and diluted EPS of $6.78. HIV products alone generated $20.8 billion, with Biktarvy — the world’s best-selling HIV treatment — contributing $14.3 billion.

How old is Daniel O’Day?

Daniel O’Day is 61 years old, born on May 26, 1964. He grew up in Texas and Connecticut before attending Georgetown University and Columbia Business School.

Conclusion

Daniel O’Day has proven himself as one of the most impactful pharmaceutical CEOs of the modern era. In his seven years at the helm of Gilead Sciences, he has successfully diversified the company beyond its HIV roots, steered it through a global pandemic, executed transformative acquisitions, and brought revolutionary new medicines to market. The FDA approval of lenacapavir (Yeztugo) for HIV prevention represents the culmination of his strategic vision and may prove to be one of the most important public health advances of the decade. With Gilead’s pipeline described as the most robust in company history and revenues approaching $30 billion, O’Day has positioned the company for sustained growth in the years ahead.

Article last updated: March 2026